溶栓藥物市場－全球產業規模、佔有率、趨勢、機會與預測：按類型、應用、分銷管道、地區和競爭格局分類，2021-2031年

全球溶栓藥物市場預計將從 2025 年的 357.2 億美元成長到 2031 年的 557.8 億美元，複合年成長率達 7.71%，呈現強勁成長動能。

溶栓藥物，俗稱“溶栓藥物”，是專門用於溶解血管阻塞、恢復心臟、肺臟和大腦等重要器官血流的藥物。這一市場的成長主要受全球急性醫療緊急情況（如心肌梗塞和缺血性中風）發病率上升的推動。這些疾病需要即時介入以防止死亡或永久殘疾。此外，全球人口老化也是一個潛在的促成因素。由於老年人更容易發生血栓事件，預計這些救命療法的需求將保持穩定。

儘管這些治療方法至關重要，但由於其嚴重併發症（尤其是顱內出血）的風險較高，因此在市場推廣方面面臨巨大的障礙。這就要求對患者進行嚴格篩選，並限制治療窗口期。然而，鑑於心血管疾病在全球造成的巨大負擔，市場需求依然強勁。根據世界卒中組織2024年的數據，每年有超過1,200萬人罹患卒中，使其成為全球第二大死因。如此龐大的患者群體表明，對有效溶栓療法的需求仍然存在，同時，醫療專業人員必須重視溶栓治療過程中固有的臨床風險。

市場促進因素

全球溶栓藥物市場的主要驅動力是急性缺血性腦中風和心肌梗塞在全球範圍內的日益普遍。由於人口老化和生活方式相關的危險因素，這些危及生命的疾病的發病率不斷上升，因此，臨床上迫切需要使用快速溶栓療法來恢復血流並最大限度地減少組織損傷。患者數量的激增直接導致全球急診和中風中心對溶栓藥物的需求增加。根據美國心臟協會 (AHA) 2025 年 1 月發布的一份報告，2022 年美國僅卒中死亡人數就高達 165,393 人，這凸顯了對有效藥物療法以控制這種高致死率疾病的迫切需求。

同時，市場正經歷一場變革性的轉變，其特徵是替奈克替尼（tenecta place）和第三代溶栓療法的應用日益廣泛。由於這些新型藥物具有更高的纖維蛋白特異性、更長的半衰期以及單劑量給藥的便利性，臨床醫生越來越傾向於選擇它們而非傳統的替奈克替尼，這顯著簡化了時間緊迫的緊急情況下的工作流程。這一轉變也受到關鍵監管里程碑的推動，這些里程碑將使患者能夠獲得這些先進的治療方法。例如，基因泰克公司於2025年3月宣布，美國FDA已正式核准TNKase用於治療急性缺血性腦中風，這是近30年來該領域新核准。勃林格殷格翰公司於2025年7月報告稱，其上半年集團淨銷售額成長6.3%至140億歐元，這主要得益於其人商業性藥品部門溶栓藥物產品組合的出色表現，也反映了該領域強勁的商業發展勢頭。

市場挑戰

溶栓藥物市場商業性擴張的主要限制因素是其發生嚴重併發症（尤其是顱內出血）的高風險。由於副作用可能危及生命，醫療專業人員在開立這些強效藥物時極為謹慎。這種臨床謹慎導致了嚴格的患者篩檢方案和有限的治療時間，實際上將相當一部分患者排除在治療之外。因此，安全問題阻礙了溶栓藥物的廣泛應用，實際目標市場遠小規模血栓性疾病總發生率所預期的市場規模。

這種限制直接阻礙了銷售量成長，因為它將這些藥物的使用範圍限定在最合格的患者群體中。根據美國心臟協會2024年的數據，美國因急性缺血性腦中風住院的患者中，接受靜脈溶栓治療的比例不足20%。這主要是由於出血風險相關的禁忌症以及就診延遲等原因造成的。如此低的使用率表明，安全障礙和嚴格的合格標準仍然限制著該領域製造商的潛在收入。

市場趨勢

將人工智慧 (AI) 應用於快速中風分診和治療方法選擇，正在重塑市場格局，加速識別符合溶栓治療條件的患者。先進的 AI 演算法現在可以即時分析 CT 影像，自動識別大血管閉塞 (LVO) 並通知中風團隊，從而避免人工操作造成的延誤。這種自動化直接解決了溶栓藥物給藥時間緊迫的關鍵挑戰，減少了因診斷瓶頸而錯失治療良機的患者數量。根據 NeurologyLive 在 2025 年 2 月報道，在國際卒中大會上公佈的數據顯示，RapidAI 平台成功準確識別了 98% 的 LVO，顯著優於其他診斷工具，確保更多患者能夠快速分診並立即接受藥物治療。

同時，移動卒中單元（MSU）的擴展正將救治重心轉移到院前階段，從而擴大了可治療的患者群體。這些單元配備移動CT掃描儀，使醫療團隊能夠現場診斷缺血性中風並給予溶栓藥物，顯著縮短了從發病到開始治療的時間。這種模式顯著提高了溶栓藥物的使用率，而溶栓藥物的使用往往受限於病人到達醫院和登記流程的延誤。根據美國心臟協會（AHA）2025年1月發布的回顧性研究，由移動中風單元（MSU）轉運的患者接受組織型胞漿素原原活化劑（tPA）治療的可能性顯著更高。其給藥率為49.9%，而使用標準急救服務的患者僅9.4%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球溶栓藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（纖維蛋白特異性藥物、非纖維蛋白特異性藥物）
  • 依應用領域（心肌梗塞、肺動脈栓塞、深層靜脈栓塞症、急性缺血性腦中風等）
  • 銷售管道細分（零售藥局、醫院藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美溶栓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲溶栓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區溶栓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲溶栓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲溶栓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球溶栓藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Genentech Inc.
• Dr. Reddy's Laboratories
• Bayer AG
• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim Gmbh
• Sanofi
• Merck & Co

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Clot Buster Drugs Market is projected to experience robust growth, expanding from a valuation of USD 35.72 Billion in 2025 to USD 55.78 Billion by 2031, reflecting a compound annual growth rate of 7.71%. Thrombolytic agents, commonly referred to as clot busters, are specialized pharmaceutical formulations engineered to dissolve vascular blockages, thereby restoring essential blood flow to critical organs like the heart, lungs, and brain. The market's upward trajectory is primarily driven by the rising global incidence of acute medical emergencies, such as myocardial infarction and ischemic stroke, which demand immediate intervention to prevent fatality or permanent injury. Additionally, the rapidly aging global population acts as a fundamental driver, as older demographics are naturally more susceptible to thrombotic events, ensuring a steady demand for these life-saving therapies.

Despite the indispensable nature of these treatments, the market faces significant hurdles due to the high risk of severe complications, most notably intracranial hemorrhage, which necessitates strict patient selection and narrow therapeutic windows. However, the demand remains substantial given the immense global burden of cardiovascular diseases. Data from the World Stroke Organization in 2024 indicates that stroke affects over 12 million individuals annually and ranks as the second leading cause of death worldwide. This vast patient volume underscores the enduring need for effective thrombolytic options, even as healthcare providers navigate the inherent clinical risks associated with their administration.

Market Driver

The primary catalyst propelling the Global Clot Buster Drugs Market is the escalating global prevalence of acute ischemic stroke and myocardial infarction. As these life-threatening conditions become more frequent, largely due to aging populations and lifestyle-associated risk factors, there is an intensified clinical urgency to utilize rapid thrombolysis to restore perfusion and minimize tissue damage. This surge in patient numbers directly correlates with increased procurement of fibrinolytic agents by emergency departments and stroke centers worldwide. According to the American Heart Association in January 2025, stroke alone accounted for 165,393 deaths in the United States during 2022, highlighting the critical and growing necessity for effective pharmaceutical interventions to manage this high-mortality condition.

Simultaneously, the market is undergoing a transformative shift characterized by the increasing adoption of tenecteplase and third-generation thrombolytic therapies. Clinicians are progressively favoring these newer agents over traditional alteplase due to their enhanced fibrin specificity, longer half-life, and the logistical advantage of single-bolus administration, which significantly streamlines workflows in time-critical emergency settings. This transition is further bolstered by major regulatory milestones that expand patient access to these advanced treatments; for instance, Genentech announced in March 2025 that the U.S. FDA officially approved TNKase for acute ischemic stroke, the first new approval in this category in nearly three decades. Reflecting the strong commercial momentum in this sector, Boehringer Ingelheim reported in July 2025 a 6.3% increase in group net sales to EUR 14.0 billion for the first half of the year, driven substantially by the performance of its Human Pharma division's thrombolytic portfolio.

Market Challenge

A major restraint on the commercial expansion of the clot buster drugs market is the substantial risk of severe complications, particularly intracranial hemorrhage. Medical professionals exercise extreme caution when prescribing these potent pharmaceutical agents, as the adverse effects can be life-threatening. This clinical vigilance results in rigorous patient screening protocols and enforces restricted therapeutic windows, effectively excluding a significant portion of the patient population from receiving treatment. Consequently, the actual addressable market is considerably smaller than the total incidence of thrombotic conditions would suggest, as safety concerns prevent broader adoption.

This limitation directly hampers volume growth by restricting the usage of these drugs to only the most eligible candidates. According to the American Heart Association in 2024, intravenous thrombolysis was administered in less than 20 percent of patients admitted with acute ischemic stroke in the United States, largely due to contraindications related to bleeding risks and delayed presentation. This low utilization rate demonstrates how safety barriers and strict eligibility criteria persistently cap the revenue potential for manufacturers in this sector.

Market Trends

The integration of artificial intelligence into rapid stroke triage and treatment selection is reshaping the market by accelerating the identification of candidates for thrombolytic therapy. Advanced AI algorithms now analyze CT imaging instantaneously, automatically flagging large vessel occlusions (LVOs) and notifying stroke teams to bypass manual delays. This automation directly addresses the critical time-sensitivity of administering clot-busting drugs, ensuring that fewer patients miss the therapeutic window due to diagnostic bottlenecks. As reported by NeurologyLive in February 2025, data presented at the International Stroke Conference revealed that the RapidAI platform successfully identified 98% of large vessel occlusions, significantly outperforming other diagnostic tools and ensuring that a higher volume of patients can be rapidly triaged for immediate pharmaceutical management.

In parallel, the expansion of Mobile Stroke Units (MSUs) is increasing the reachable patient population by shifting care to the pre-hospital setting. These units, equipped with onboard CT scanners, allow medical teams to diagnose ischemic stroke and administer thrombolytics at the scene, drastically reducing onset-to-treatment times. This model significantly increases the utilization rates of thrombolytic agents, which are often limited by delays in hospital arrival and processing. According to the American Heart Association in January 2025, a retrospective study demonstrated that patients transported by Mobile Stroke Units were significantly more likely to receive tissue-type plasminogen activator, with an administration rate of 49.9% compared to only 9.4% for those utilizing standard emergency services.

Key Market Players

• Genentech Inc.
• Dr. Reddy's Laboratories
• Bayer AG
• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim Gmbh
• Sanofi
• Merck & Co

Report Scope

In this report, the Global Clot Buster Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clot Buster Drugs Market, By Type

• Fibrin Specific Drugs
• Non-Fibrin Specific Drugs

Clot Buster Drugs Market, By Application

• Myocardial Infarction
• Pulmonary Embolism
• Deep Vein Thrombosis
• Acute Ischemic Strokes
• Others

Clot Buster Drugs Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Clot Buster Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clot Buster Drugs Market.

Available Customizations:

Global Clot Buster Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clot Buster Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Fibrin Specific Drugs, Non-Fibrin Specific Drugs)
  • 5.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Clot Buster Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clot Buster Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Clot Buster Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Clot Buster Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Clot Buster Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clot Buster Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Clot Buster Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Clot Buster Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Clot Buster Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Clot Buster Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Clot Buster Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Clot Buster Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Clot Buster Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Clot Buster Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Clot Buster Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Clot Buster Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Clot Buster Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Clot Buster Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Clot Buster Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Clot Buster Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Clot Buster Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Clot Buster Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Clot Buster Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Clot Buster Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Clot Buster Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Genentech Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Dr. Reddy's Laboratories
• 15.3. Bayer AG
• 15.4. Eli Lilly and Company
• 15.5. Pfizer Inc.
• 15.6. Johnson & Johnson Services Inc
• 15.7. Sun Pharmaceutical Industries Ltd.
• 15.8. Boehringer Ingelheim Gmbh
• 15.9. Sanofi
• 15.10. Merck & Co

16. Strategic Recommendations

17. About Us & Disclaimer